Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Required: SLFN11 positive (positive)

Cannot have received: immune checkpoint inhibitor

Exception: therapeutic anti-tumor vaccines

No previous treatment with immune checkpoint inhibitors and PARP inhibitors, including but not limited to other anti-PD-1, anti-PD-L1 and anti-programmed cell death ligand 2 (anti-PD-L2) antibodies, with the exception of therapeutic anti-tumor vaccines

Cannot have received: PARP inhibitor

No previous treatment with ... PARP inhibitors

Cannot have received: chemotherapy

No prior chemotherapy or radiation therapy to the chest lesion

Cannot have received: radiation therapy

Exception: external chest radiotherapy for palliative purposes (e.g., bone metastases) is allowed, but must be completed prior to the first administration of study drug

No prior chemotherapy or radiation therapy to the chest lesion. History of thoracic radiotherapy or plan to receive intensive thoracic radiotherapy prior to systemic therapy. External chest radiotherapy for palliative purposes (e.g., bone metastases) is allowed, but must be completed prior to the first administration of study drug

Cannot have received: systemic antitumor therapy

Prior systemic antitumor therapy (chemotherapy, targeted agents such as PARP inhibitors) or immune checkpoint inhibitors for SCLC

Cannot have received: allogeneic stem cell transplant

Previous allogeneic stem cell or solid organ transplantation